Year: 2025

Belharra Therapeutics Announces Appointment of Sean Buchanan, Ph.D., as Chief Scientific Officer and Retirement of Gary O’Neill, Ph.D.

Dr. Buchanan will helm Belharra’s research organization as the company progresses its lead immunology and oncology programs, advances activities with...

Arvinas Updates Guidance for First- and Second-Line Phase 3 Combination Trials with Vepdegestrant, Highlights Upcoming Milestones, and Provides Corporate Update

– Vepdegestrant to be combined with Pfizer’s novel investigational CDK4 inhibitor atirmociclib in a first-line Phase 3 trial planned to...

GH Research Announces Primary Endpoint Met in Two Phase 2a POC Trials with GH001 and Completion of All FDA Requests to Address IND Hold with No Findings of Respiratory Toxicity in Non-Rodents

Population Health Management Market size to increase by USD 19.40 Billion between 2024 to 2029, Market Segmentation by Component, End-user, Geography , Technavio

NEW YORK, Jan. 9, 2025 /PRNewswire/ -- The global population health management market size is estimated to grow by USD 19.40...

AI Wellness Unveils Mission 2025 at CES–Revolutionizing Health, Education, and Philanthropy with Digital Avatars, Wellness Bundles, and the Ask My Avatar Challenge

LAS VEGAS, Jan. 9, 2025 /PRNewswire/ -- AI Wellness (Assisted Intelligence Wellness) is taking center stage at CES 2025 with Mission...

error: Content is protected !!